SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor is drawing attention ahead of the FDAs November 22 target decision on deramiocel for Duchenne muscular dystrophy, with traders weighing whether the amended application and longer-term upper-limb data could support approval. Bullish speculation has been reinforced by commercial-launch job postings and optimism about FDA flexibility, while skeptics cite prior advisory-panel concerns and caution that hiring does not guarantee approval; INOs separate FDA approval has also provided a sentiment tailwind.

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 636,822,022.65079832 with 590,150,211.79771733 in circulation. The last known price of Solana is 94.05303263 USD and is down -1.56 over the last 24 hours. It is currently trading on 1189 active market(s) with $1,556,044,818.54 traded over the last 24 hours. More information can be found at https://solana.com.

Solana

Solana is drawing attention amid a broad crypto pullback, with traders debating whether concerns over Binances reported security incident and exchange trust are adding pressure or coinciding with an existing market downtrend. Sentiment is split between bearish calls for further weakness and buyers treating the decline as an opportunity to accumulate and stake.

Cardano (ADA) is a cryptocurrency launched in 2017. Cardano has a current supply of 44,994,665,205.855202 with 36,823,860,963.224877 in circulation. The last known price of Cardano is 0.19280151 USD and is up 0.00 over the last 24 hours. It is currently trading on 1752 active market(s) with $154,401,668.14 traded over the last 24 hours. More information can be found at https://www.cardano.org.

Cardano

ADAs volatile price action and technical levels dominate the discussion, with traders debating whether rebounds and breakout setups can hold or whether further weakness will follow. Sentiment is sharply divided between dip-buying and short-squeeze hopes on one side, and concerns about continued losses and a lack of altcoin momentum on the other.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPengs record October deliveries, including sharply higher overseas sales, are driving discussion, but traders are debating whether volume growth can translate into better margins and meet the companys Q4 delivery ambitions. The upbeat operating update is being weighed against a steep share-price decline and concerns about China EV competition and profitability.

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,809.831273 with 281,866,746.118905 in circulation. The last known price of OFFICIAL TRUMP is 1.73532194 USD and is up 9.97 over the last 24 hours. It is currently trading on 744 active market(s) with $259,407,006.57 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

A modest rebound has prompted pump and short-squeeze chatter around the Trump-themed meme coin, while most discussion focuses on its steep decline and accusations that it is a speculative pump-and-dump. Some holders remain bullish, but skeptics warn of further losses.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOI is drawing attention after a sharp selloff alongside AI and optical peers, with traders pointing to broader risk-off sentiment and concerns about dilution, valuation, and execution rather than a clear company-specific setback. Bulls are buying the dip on data-center optics demand and upcoming earnings, while skeptics remain wary of further declines.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A sharp breakout to a 52-week high ahead of the Q3 report is driving attention, with bullish traders pointing to BRIUMVIs commercial growth and speculating about a short squeeze or buyout. Others caution that the buyout talk is unconfirmed and that the earnings results and upcoming subcutaneous BRIUMVI data will be important tests of the rally.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Positioning around Luckins scheduled third-quarter earnings report is the main focus, with traders hoping for strong results and a rally while others expect a post-report pullback. The debate is amplified by frustration over the stocks prolonged weak, range-bound trading and speculation about buybacks or a future relisting.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxons quarterly earnings beat and strong refining results are driving attention, with traders highlighting higher shareholder returns and record-high shares. The reaction is broadly positive, though some caution that the stock looks extended and refining strength may not last if margins normalize.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gileads strong third-quarter results and raised outlook, led by continued HIV drug demand, are driving attention as shares reach fresh highs. Traders are broadly upbeat about the earnings and breakout, though some remain cautious after the run-up.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

P&Gs stronger-than-expected quarterly results have supported a sharp rally, with traders also treating the consumer-staples giant as a defensive play amid weakness in technology stocks. The bullish reaction is tempered by concerns about commodity-driven margin pressure and whether modest growth justifies the stocks valuation.

Coca-Cola and Procter & Gamble Are Up This Month. Which Dow Dividend Stock Is the Better Buy Now?

Key PointsCoca-Cola and Procter & Gamble have both rallied sharply over the past month...

Procter & Gamble is Accelerating Revenue Growth as its Costs are Rising

Should you buy stock in Procter & Gamble right now?
Before you buy stock in Procter & Gamble, consider this:Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in...

3 Magnificent Dividend Stocks for Risk-Averse Investors

Key PointsConsumer goods giant Procter & Gamble's sheer size is a proven competitive edge...

Here's How Many Shares of Procter & Gamble It Would Take to Fund an Annual $3,000 Vacation From Dividends

Key PointsAbout 690 shares would pay roughly $3,000 a year at the current dividend...

Strategic Exercise: Shailesh Jejurikar Decides To Exercise Options Worth $2.83M At Procter & Gamble

Highlighted on October 26, it was unveiled in an SEC filing that Jejurikar, Chairman at Procter & Gamble (NYSE:PG), executed a significant transaction involving the exercise of company stock options.
What Happened:read more...

Santoli: We are nearing a now-or-never moment for the AI trade to rebound

Pampers over AI? Procter & Gamble's valuation crosses above Alphabet's...

Is Trending Stock Procter & Gamble Company (The) (PG) a Buy Now?

Zacks.com users have recently been watching P&G (PG) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Take the Zacks Approach to Beat the Markets: Honda Motor, Accenture, CACI in Focus

HMC, CACI and ACN lead Zacks' stock success stories, with standout returns across multiple research portfolios despite market uncertainty.

Procter & Gamble's Earnings Show a Resilient Consumer Despite Price Hikes. Is the Dividend King Stock a Buy?

Key PointsThe household products giant reported 4% organic sales growth in its Q1...

Procter & Gamble's Turnaround Gains Steam, but Analyst Warns Rising Oil Costs Could Threaten Recovery

TD Cowen raises Procter & Gamble's price target to $166 after Q1 beat, but maintains a Hold on rising commodity costs.read more...

• Reported GAAP EPS of $2.00 up 0.50% YoY
• Reported revenue of $23.28B up 3.98% YoY
• The Procter & Gamble Company updated FY 2027 all-in sales growth guidance to +2% to +4% for Thorne and maintained organic sales growth of +1% to +3% and Core EPS growth of in-line to +3%.

Procter & Gamble reported gross margin decreased 160 basis points and core operating margin decreased 80 basis points, expects a $0.79-per-share FY 2027 headwind, and cites competitors technology advances and patents as risks.

Procter & Gamble delivered 4% organic sales growth, including 5% Grooming growth from innovation-based pricing and favorable mix, while generating 93% free cash flow productivity and returning $3.9B to shareowners.

Procter & Gamble Co. engages in the provision of branded consumer packaged goods. It operates through the following segments: Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine and Family Care. The Beauty segment offers hair, skin, and personal care. The Grooming segment consists of shave care like female and male blades and razors, pre and post shave products, and appliances. The Health Care segment includes oral care products like toothbrushes, toothpaste, and personal health care such as gastrointestinal, rapid diagnostics, respiratory, and vitamins, minerals, and supplements. The Fabric and Home care segment consists of fabric enhancers, laundry additives and detergents, and air, dish, and surface care. The Baby, Feminine and Family Care segment sells baby wipes, diapers, and pants, adult incontinence, feminine care, paper towels, tissues, and toilet paper. The company was founded by William Procter and James Gamble in 1837 and is headquartered in Cincinnati, OH.

Procter & Gamble Co.

P&G’s Q1 Results Draw Price-Target Hikes As Analysts Cite Stronger Underlying Performance 

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>RBC Capital analyst Nik Modi maintained an ‘Outperform’ rating on P&amp;G, citing organic sales growth across every category, strong underlying results excluding one-time factors, and encouraging top-line fundamentals, according to The Fly.</li><li>Wells Fargo raised its price target on P&amp;G to $180 from $164, maintaining an ‘Overweight’ rating, and cited strong organic sales growth and potential upside to sales guidance.</li><li>According to Koyfin data, 13 of 25 analysts covering P&amp;G rate the stock ‘Buy’ or ‘Strong Buy,’ while 12 rate it ‘Hold.’</li></ul><p>Procter &amp; Gamble’s (PG) shares drew investor attention on Friday after multiple analysts raised their price targets following the company’s better-than-expected fiscal first-quarter results.</p><p>According to The Fly, Deutsche Bank said the quarter provided the “clearest evidence yet” that P&amp;G’s category and customer interventions, innovation, and efforts to restore superiority were translating into better underlying performance. The firm raised its price target on P&amp;G to $176 from $162 and maintained a ‘Buy’ rating on the shares.</p><p><a href="https://stocktwits.com/symbol/PG">PG shares&nbsp;</a>traded 1.6% lower at the time of writing.</p><p>According to Koyfin data, 12 out of 25 analysts covering the stock rate it ‘Hold’, whereas 13 rate the stock ‘Buy’ or ‘Strong Buy’.</p><h2 class="st-heading-2">Analysts Raise Price Targets On P&amp;G</h2><p>RBC Capital analyst Nik Modi raised his price target to $169 from $166 and maintained an ‘Outperform’ rating. According to The Fly, Modi said P&amp;G reported a strong quarter, with organic sales growth across every category and underlying results remaining strong after excluding one-time factors. He added that topline fundamentals were encouraging, share recovery continued to build, and P&amp;G had levers to manage the elevated cost environment.</p><p>Meanwhile, Morgan Stanley raised its price target to $185 from $166 and maintained an ‘Overweight’ rating. The analyst said brand interventions and recent reinvestment had “begun to bear fruit,” pointing to strong organic sales growth in Q1. The firm also viewed P&amp;G as well positioned on a relative earnings-per-share (EPS) basis in a “tough HPC environment.”</p><p>Wells Fargo raised its price target to $180 from $164 and maintained an ‘Overweight’ rating on P&amp;G, according to The Fly. The firm noted that the company recorded its strongest organic sales growth in nearly three years and that comparisons would become easier in the second and fourth quarters.&nbsp;</p><p>Wells Fargo added that this put upside to reiterated topline guidance “well in scope,” alongside prospects for improving confidence in fiscal 2027 EPS despite higher inflation.</p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Analyst</td><td>Old PT</td><td>New PT</td></tr><tr><td>Deutsche Bank</td><td>$162</td><td>$176</td></tr><tr><td>JPMorgan</td><td>$162</td><td>$180</td></tr><tr><td>RBC Capital</td><td>$166</td><td>$169</td></tr><tr><td>Citi</td><td>$180</td><td>$187</td></tr><tr><td>Morgan Stanley</td><td>$166</td><td>$185</td></tr><tr><td>Wells Fargo</td><td>$164</td><td>$180</td></tr><tr><td>Goldman Sachs</td><td>$150</td><td>$161</td></tr></tbody></table></figure></div><h2 class="st-heading-2">P&amp;G’s Fiscal Q1 Earnings Highlights</h2><p>Procter &amp; Gamble maintained its fiscal 2027 organic sales growth outlook of 1%–3% and core EPS growth outlook of in-line to 3%, equivalent to $6.89–$7.11 per share. The company raised its fiscal 2027 all-in sales growth outlook to 2%–4%, reflecting its acquisition of Thorne, effective October 1, 2026.</p><p>P&amp;G reported adjusted earnings of $2.00 per share, beating analyst estimates of $1.89 per share, while revenue of approximately $23.28 billion topped estimates of $22.82 billion, according to estimates compiled by Fiscal AI.</p><p>The company also raised its estimated fiscal 2027 after-tax commodity cost headwind to approximately $1.4 billion, citing higher raw-material, energy and transportation costs.&nbsp;</p><h2 class="st-heading-2">How Retail Views PG</h2><p>On Stocktwits, retail sentiment remained in the ‘bullish’ territory amid ‘high’ message volumes.&nbsp;</p><p>PG shares have gained 13% year-to-date.</p><p><strong>Also read: </strong><a href="https://stocktwits.com/news-articles/markets/equity/dan-ives-calls-ai-sell-off-saas-apocalypse-2-0-oracle-in-toughest-spot/cZxyK1wRBxF"><strong>Dan Ives Calls AI Sell-Off ‘SaaS Apocalypse 2.0,’ Says Oracle Is ‘In The Toughest Spot’</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Procter & Gamble (P&G) logo is seen during the 6th China International Import Expo (CIIE) at the National Exhibition and Convention Center (Shanghai) on November 7, 2023 in Shanghai, China. (Photo by VCG/VCG via Getty Images)

Procter & Gamble’s (PG) shares drew investor attention on Friday after multiple analysts raised their price targets following the company’s better-than-expected fiscal first-quarter results.

P&G’s Q1 Results Draw Price-Target Hikes As Analysts Cite Stronger Underlying Performance

According to The Fly, Morgan Stanley raised its price target on P&G to $185 from $166, maintaining an ‘Overweight’ rating, and said recent brand interventions and reinvestment had “begun to bear fruit.”



Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Futures

Fundamentals

Info

PG Futures

PG Single Stock Futures